Given the interest in the emerging and evolving coronavirus (COVID-19) pandemic and the questions regarding how this will impact patients with atopic dermatitis (AD) who are treated with systemic immunomodulating medication, we have created an international, secure, online, de-identified Personal Health Identifier (PHI)-free reporting registry: the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE)-AD registry.
We encourage healthcare providers to report outcomes of COVID-19 in their AD patients who are treated with and without systemic immunomodulating medication. By collecting worldwide observational data on cases of COVID-19 in AD patients, the SECURE-AD registry will enable description of the impact of COVID-19 on these patients and how factors such as age, comorbidities, and AD systemic immunomodulating treatments impact COVID-19 outcomes.
The SECURE-AD registry is supported by the International Society for Atopic Dermatitis (ISAD), the International League of Dermatological Societies (ILDS), the European Task Force on Atopic Dermatitis (ETFAD), the European Dermato-Epidemiology Network (EDEN), the European Dermatology Forum (EDF) and the Skin Inflammation and Psoriasis International Network (SPIN).
]Through broadscale participation and collaboration the data collected through the SECURE-AD registry will benefit the entire AD patient population and international clinical community. Reporting a case should take approximately 5 minutes. The SECURE-AD registry is accessible via www.covidderm.org.